Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 21,430 matching trials from the live ClinicalTrials.gov search.
Conditions
Relapsed, Refractory Multiple Myeloma
Interventions
RAPA-201 Autologous T cells
Biological
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
semaxanib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Corneal Persistent Epithelial Defect
Interventions
Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Interventions
Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin, Carboplatin, Capecitabine, 5FU, Liver transplantation
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Lymphoma
Interventions
bortezomib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
sorafenib tosylate, bevacizumab
Drug · Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
211
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 134 more
Conditions
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Interventions
rezatapopt, pembrolizumab
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 26 more
Conditions
Leukemia, Mantle Cell Lymphoma, Myelofibrosis
Interventions
RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
Interventions
Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Fluorothymidine F-18, Irinotecan Hydrochloride, Positron Emission Tomography, Therapeutic Conventional Surgery
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy, Coronary Artery Disease
Interventions
PB127 for Injectable Suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
16
States / cities
Long Beach, California • San Diego, California • Newark, Delaware + 11 more
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
trastuzumab, Pertuzumab, docetaxel, carboplatin, doxorubicin, cyclophosphamide, paclitaxel, Bevacizumab
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Indolent Systemic Mastocytosis
Interventions
Avapritinib, Placebo
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more
Conditions
Non-small Cell Lung Cancer
Interventions
BMS-275183
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Sacramento, California • New Haven, Connecticut • Atlanta, Georgia + 4 more
Conditions
Higher-risk Myelodysplastic Syndromes
Interventions
AK117, Placebo, Azacitidine
Drug
Lead sponsor
Akeso
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more
Conditions
Myelodysplastic Syndrome
Interventions
pracinostat, Placebo, Azacitidine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Mobile, Alabama • La Jolla, California • Denver, Colorado + 21 more
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
PDC-1421 Capsule
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Conditions
Leukemia, Other, Cancer
Interventions
Gleevec and Arsenic Trioxide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Conditions
Mantle Cell Lymphoma
Interventions
Pirtobrutinib, Rituximab, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Conditions
Lung Cancer
Interventions
Carboplatin, Proton Radiotherapy, Paclitaxel
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
Interventions
Paclitaxel + Carboplatin, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Small Cell
Interventions
Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Dallas, Texas
Conditions
Metastatic Melanoma
Interventions
Sutent (sunitinib)
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

A Trial of Vitamin B12 in Septic Shock

NCT03783091
Conditions
Septic Shock
Interventions
Hydroxocobalamin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin